NASDAQ:SPROSpero Therapeutics Stock Price, Forecast & News

Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SPRO shares have increased by 67.7% and is now trading at $13.00. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spero Therapeutics.

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Spero Therapeutics.

Spero Therapeutics Inc (NASDAQ:SPRO) posted its earnings results on Friday, May, 8th. The company reported ($1.22) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.13. The firm had revenue of $1.70 million for the quarter, compared to analysts' expectations of $3.36 million. Spero Therapeutics had a negative return on equity of 88.22% and a negative net margin of 654.03%. View Spero Therapeutics' earnings history.

6 brokers have issued twelve-month price targets for Spero Therapeutics' shares. Their forecasts range from $20.00 to $28.00. On average, they anticipate Spero Therapeutics' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 76.9% from the stock's current price. View analysts' price targets for Spero Therapeutics.

Media headlines about SPRO stock have trended somewhat negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Spero Therapeutics earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutSpero Therapeutics.

Spero Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 536,900 shares, an increase of 6.5% from the April 15th total of 504,100 shares. Based on an average trading volume of 103,100 shares, the days-to-cover ratio is presently 5.2 days. Approximately 3.8% of the shares of the stock are sold short. View Spero Therapeutics' Current Options Chain.

Some companies that are related to Spero Therapeutics include INDIVIOR PLC/S (INVVY), BioXcel Therapeutics (BTAI), MacroGenics (MGNX), Athenex (ATNX), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Endo International (ENDP), Rhythm Pharmaceuticals (RYTM), ImmunoGen (IMGN), NextCure (NXTC), Cue Biopharma (CUE), Passage Bio (ORIC), Omeros (OMER), Gossamer Bio (GOSS) and Arcturus Therapeutics (ARCT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Crispr Therapeutics (CRSP), Viking Therapeutics (VKTX), Inovio Pharmaceuticals (INO), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), NVIDIA (NVDA), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Nokia Oyj (NOK) and Akoustis Technologies (AKTS).

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Spero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.34%), Rock Springs Capital Management LP (2.94%), VR Adviser LLC (2.30%), State Street Corp (1.37%), Granahan Investment Management Inc. MA (0.84%) and Geode Capital Management LLC (0.75%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View institutional ownership trends for Spero Therapeutics.

SPRO stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., UBS Group AG, and Deutsche Bank AG. View insider buying and selling activity for Spero Therapeutics.

SPRO stock was acquired by a variety of institutional investors in the last quarter, including VR Adviser LLC, BlackRock Inc., Rock Springs Capital Management LP, State Street Corp, DAFNA Capital Management LLC, Dupont Capital Management Corp, Geode Capital Management LLC, and Granahan Investment Management Inc. MA. View insider buying and selling activity for Spero Therapeutics.

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SPRO stock can currently be purchased for approximately $13.00.

Spero Therapeutics has a market capitalization of $267.74 million and generates $18.15 million in revenue each year. The company earns $-60,920,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Spero Therapeutics employs 57 workers across the globe.

The official website for Spero Therapeutics is sperotherapeutics.com.

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]